IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS INTERLEUKIN-13 (IL-13)) AND ANTI-(HOMO SAPIENS INTERLEUKIN-4 (B-CELL STIMULATORY FACTOR 1, BINETRAKIN, IL-4)) CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC, TETRAVALENT .GAMMA.1 HEAVY CHAIN (1-577) (VH ANTI-IL-13 (MUS MUSCULUS IGHV267*01 (84%) (IGHD)-IGHJ4*01 (94%) / HOMO SAPIENS IGHV2-26*01 (60%) (IGHD)-IGHJ1*01 (91%))) (8.7.12) (1-118) BIS(TETRAGLYCYL-SERYL)- LINKER (119-128) (VH ANTI-IL-4 (MUS MUSCULUS IGHV1S127*01 (82%) (IGHD)-IGHJ1*01 (88%) / HOMO SAPIENS IGHV1-46*01 (68%) (IGHD)-IGHJ4*01 (87%))) (8.8.16) (129-251) -HOMO SAPIENS IGHG4*01 (HINGE(S10>P(359)), CH2(L5>E(366)), CH3(K107>DEL(578))) (252-577)) (265-335')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-335') (V-KPPA ANTI-IL-13 (MUS MUSCULUS IGKV310*01 (93%) IGKJ1*01 (100%) / HOMO SAPIENS IGKV4-1*01 (72%) IGKJ4*01 (91%)) (10.3.9) (1'-111') BIS(TETRAGLYCYL-SERYL)- LINKER (112'-121') (HUMANIZED V-KAPPA ANTI-IL-4 (HOMO SAPIENS IGKV1-12*01 (77%) IGKJ2*02 (91%)) (6.3.9) (122'-228')) -HOMO SAPIENS IGKC*01 (229'-335')) DIMER (357-357'':360-360'')-BISDISULFIDE
Idiopathic Pulmonary Fibrosis
Sanofimonoclonal_antibodyPhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 73/ 100
Competitive context
111 Active assets in the Idiopathic Pulmonary Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pirfenidone Endeavor Biomedicines, Inc. | Phase 4 | A |
N-Acetyl-L-Cysteine Endeavor Biomedicines, Inc. | Phase 4 | BBB |
Nintedanib Mannkind Corporation | Phase 4 | BBB |
PREDNISONE TABLETS Fondation Hôpital Saint-Joseph | Phase 3 | BB |
hsk44459 Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →